nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

20.09.2019 | short review

CML at the 2018 ASH meeting—selected presentations

verfasst von: Dr. Stefan Schmidt

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Summary

Treatment recommendations in chronic myeloid leukemia (CML) treatment have not changed substantially since treatment-free remission (TFR) has become a therapeutic option. Hence, allowing more patients to enter TFR is gaining significance. Although, Asciminib as a first-in-class new type of tyrosine kinase inhibitor (TKI) is in clinical development, currently combination treatment with TKIs and Interferon-alpha2b appears the best option to deepen molecular response and broaden the basis of potential TFR candidates. Improving the chances of a first successful TFR has to be the primary goal in TFR optimization as even re-induction of a deep molecular response after TFR failure using second generation TKIs shows disillusioning results.

Vorheriger Artikel Post San Antonio

Nächster Artikel Highlights on chronic lymphocytic leukemia presented at the 2018 American Society of Hematology Meeting

Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–20.CrossRefPubMed

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–51.CrossRefPubMedPubMedCentral

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84.CrossRefPubMedPubMedCentral

Radich J, Deininger M, Abboud C, Altman J, Berman E, Bathia A, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J. NCCN guidelines version 1.2019 chronic myeloid leukemia 2019.. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed: 12. Jan. 2019.

Hochhaus A. ESMO clinical practiceguidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv41–iv51. https://doi.org/10.1093/annonc/mdx219.CrossRefPubMed

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM‑L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7.CrossRefPubMed

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of Imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398.CrossRefPubMedPubMedCentral

Gambacorti-Passerini C, Antolini L, Mahon F‑X, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with Imatinib. J Natl Cancer Inst. 2011;103(7):553–61.CrossRefPubMed

Bettiol A, Marconi E, Lombardi N, Crescioli G, Gherlinzoni F, Walley T, et al. Pattern of use and long-term safety of tyrosine kinase inhibitors: a decade of real-world management of chronic myeloid leukemia. Clin Drug Investig. 2018;38(9):837–44.CrossRefPubMed

10.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of Imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–22.CrossRefPubMed

11.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–30.CrossRefPubMed

12.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–57.CrossRefPubMed

13.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, et al. Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients. Clin Cancer Res. 2019. https://doi.org/10.1158/1078-0432.CCR-18-3373.CrossRef

14.

Legros L, Rousselot P, Giraudier S, Tulliez M, Huguet F, Nicolini FE, et al. Second attempt to discontinue Imatinib in CP-CML patients with a second sustained complete molecular response. Blood. 2012;120(9):1959–60.CrossRefPubMedPubMedCentral

15.

Kim DDH, Busque L, Forrest DL, Savoie L, Bence-Bruckler I, Couban S, et al. Second attempt of TKI discontinuation with dasatinib for treatment-free remission after failing first attempt with Imatinib: treatment-free remission accomplished by dasatinib (TRAD) trial. Blood. 2018;132(Suppl 1):787.CrossRef

16.

Yeung DT, Grigg AP, Shanmuganathan N, Cunningham I, Shortt J, Rowling P, et al. Combination of nilotinib and pegylated interferon alfa-2b results in high molecular response rates in chronic phase CML: interim results of the ALLG CML 11 pinnacle study. Blood. 2018;132(Suppl 1):459.CrossRef

17.

Hochhaus A, Saussele S, Baerlocher GM, Brümmendorf TH, Burchert A, La Rosée P, et al. Nilotinib vs nilotinib plus pegylated interferon-alpha2b induction and nilotinib or pegylated interferon-alpha2b maintenance therapy for newly diagnosed BCR-ABL+ chronic myeloid leukemia patients in chronic phase: interim analysis of the tiger (CML V)-study. Blood. 2018;132(Suppl 1):460.CrossRef

18.

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525.CrossRefPubMedPubMedCentral

19.

Roy L, Chomel J‑C, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, et al. Combination of dasatinib and peg-interferon Alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: preliminary results of a phase II trial, from the French intergroup of CML (Fi-LMC). Blood. 2015;126(23):134.CrossRef

20.

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5‑year study results of DASISION: the dasatinib versus Imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40.CrossRefPubMedPubMedCentral

21.

Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Hoglund M, Dreimane A, et al. Safety and efficacy of the combination of pegylated Interferon-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 2016;30(9):1853–60.CrossRefPubMed

22.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus pegInterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511–21.CrossRefPubMed

23.

Ren X, Qin Y, Huang X, Zuo L, Jiang Q. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Ann Hematol. 2019;98(7):1627–40.CrossRefPubMed

24.

Rea D, Lang F, Kim D‑W, Cortes JE, Hughes TP, Minami H, et al. Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial. Blood. 2018;132(Suppl 1):792.CrossRef

Titel: CML at the 2018 ASH meeting—selected presentations
verfasst von: Dr. Stefan Schmidt
Publikationsdatum: 20.09.2019
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-00529-4

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Skin tumours in organ transplant recipients—implications for the plastic surgeon

Cure is not enough! Why it is time to act and close the gap

News from ASH 2018—how can we afford innovation in the future?

Risk of cancer after long-term therapy of autoimmune disorders with glucocorticoids or DMARDs—a controversial issue

Immunosuppression and its complications

ASH 2018 — aggressive lymphoma